First generation or second generation EGFR tyrosine kinase inhibitors are currently the
standard of care for the first-line management of non-small cell lung cancer (NSCLC) …

First-and second-generation epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (TKIs) are the evidence-based first-line treatment for metastatic non-small-cell lung …

Activating mutations of the epidermal growth factor receptor gene (EGFR) are a driving force
for some lung adenocarcinomas. Several randomized phase III studies have revealed that …

Sensitizing mutations in the epidermal growth factor receptor (EGFR) predict response to
EGFR tyrosine kinase inhibitors (TKIs) and both first-and second-generation TKIs are …

© Translational lung cancer research. All rights reserved. Transl Lung Cancer Res 2018; 7
(Suppl 2): S165-S170 tlcr. amegroups. com the mechanisms of acquired resistance to EGFR …

Importance The survival of patients with advanced non–small cell lung cancer (NSCLC) with
epidermal growth factor receptor (EGFR) gene mutations has improved substantially in the …

The availability of 3 generations of epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (TKIs) with different pharmacologic characteristics and clinical profiles has …

Background: Lung cancer is the leading cause of cancer mortality, being responsible for
more than 1.6 million deaths each year worldwide and non-small-cell lung cancer (NSCLC) …

Mutations in the EGFR occur in approximately 10–35% of non-small-cell lung cancer
(NSCLC) patients. Osimertinib is a third-generation oral small molecule inhibitor of EGFR …

The identification of epidermal growth factor receptor (EGFR) mutations represented a
fundamental step forward in the treatment of advanced non-small cell lung cancer (NSCLC) …